TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06974084: A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastat

Sponsor: HealthBio, Inc. · Phase: PHASE2/PHASE3 · Area: INFECTIOUS_VACCINE · Target Enrollment: 252 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$11,477,760

Rescue Site Savings

+$7,568,148

Unlock Full NCT06974084 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06974084 Rescue Dossier →